Skip to content

Washington Announces Tariff Waiver for Specific Indian Medicines

By News Analysis India · · 1 min read

The U.S. Commerce Department released a list of Indian‑origin pharmaceutical commodities that will enter the United States duty‑free. Eligible items include rare‑disease orphan drugs, radiological medicines, plasma‑derived therapies, fertility agents, cellular and gene‑based treatments, and antibody‑drug conjugates.

The waiver is timed with a broader policy that will levy a 100 % tariff on certain patented drugs and the raw materials used to produce them beginning September 29. Only the products highlighted in the April presidential proclamation receive the zero‑tariff treatment.

Countries such as Argentina, Bangladesh, Japan, the EU, and others are also eligible, contingent upon their existing trade and security frameworks with the United States.